Screener
Pfizer PFE Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Pfizer’s reported figures.
Based on the most recent quarter.
The source filing: Pfizer’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 7:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000078003-26-000054
FAQ
- What is Pfizer's debt-to-equity?
- Pfizer (PFE) reported debt-to-equity of 0.7× in Q1 2026.
- How has Pfizer's debt-to-equity changed year-over-year?
- Pfizer's debt-to-equity increased by 5.2% year-over-year, from 0.7× to 0.7×.
- What is the long-term trend for Pfizer's debt-to-equity?
- Over 5 years (2020 to 2025), Pfizer's debt-to-equity has grown at a 3.9% compound annual growth rate (CAGR), from 0.6× to 0.8×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Pfizer's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude